BCL2L1 and neoplasm: Although BCL-XL PROTACs did not kill the above cancer cells in vitro, DT2216 treatment resulted in significantly reduced tumor growth of the tested models—including Renca (Fig. 3a), MC38 (Fig. 3b), and Py8119 (Fig. 3c) tumors in WT immunocompetent mice.